Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction

Journal of Experimental Medicine

Volumn 197, Issue 5, 2003, Pages 615-624

  Askari, Arman T ^a   Brennan, Marie Luise ^a   Zhou, Xiaorong ^a   Drinko, Jeanne ^a   Morehead, Annitta ^a   Thomas, James D ^a   Topol, Eric J ^a   Hazen, Stanley L ^a   Penn, Marc S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chlorination; Free radical; Inflammation; Myocardial rupture; Protease activation

Indexed keywords

MYELOPEROXIDASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME RELEASE; HEART DEATH; HEART DILATATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RUPTURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; LEUKOCYTE; MONOCYTE; MOUSE; MYOCARDITIS; NEUTROPHIL; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD45; COLLAGEN; CORONARY CIRCULATION; ENZYME ACTIVATION; HUMANS; INFLAMMATION; LEUKOCYTES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; OXIDATION-REDUCTION; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITORS; SURVIVAL RATE; TIME FACTORS; VENTRICULAR REMODELING;

EID: 0037416219     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021426     Document Type: Article

References (41)

1. St. John, S.M., M.A. Pfeffer, L. Moye, T. Plappert, J.L. Rouleau, G. Lamas, J. Rouleau, J.O. Parker, M.O. Arnold, B. Sussex, et al. 1997. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 96:3294-3299.
2. Groenning, B.A., J.C. Nilsson, L. Sondergaard, T. Fritz-Hansen, H.B. Larsson, and P.R. Hildebrandt. 2000. Antire-modeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J. Am. Coll. Cardiol. 36:2072-2080.
3. Heymans, S., A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, L. Moons, G.D. Dyspersin,J.P. Cleutjens, M. Shipley, A. Angellilo, et al. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1135-1142.
4. Ducharme, A., S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, L.E. Rohde, F.J. Schoen, R.A. Kelly, Z. Werb, P. Libby, et al. 2000. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106:55-62.
5. Hazen, S.L., J.R. Crowley, D.M. Mueller, and J.W. Heinecke. 1997. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites of inflammation. Free Radic. Biol. Med. 23:909-916.
6. Eiserich, J.P., M. Hristova, C.E. Cross, A.D. Jones, B.A. Freeman, B. Halliwell, and A. van der Vliet. 1998. Formation of nitric oxide-derived inflammatory oxidants by myeloper-oxidase in neutrophils. Nature. 391:393-397.
7. Brennan, M.L., W. Wu, X. Fu, Z. Shen, W. Song, H. Frost, C. Vadseth, L. Narine, E. Lenkiewicz, M.T. Borchers, et al. 2002. A tale of two controversies: i) defining the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase deficient mice; and ii) defining the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277:17415-17427.
8. Baldus, S., J.P. Eiserich, A. Mani, L. Castro, M. Figueroa, P. Chumley, W. Ma, A. Tousson, C.R. White, D.C. Bullard, et al. 2001. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108:1759-1770.
9. Brennan, M.L., M.M. Anderson, D.M. Shih, X.D. Qu, X. Wang, A.C. Mehta, L.L. Lim, W. Shi, S.L. Hazen, J.S. Jacob, et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107:419-430.
10. Carmeliet, P., L. Kieckens, L. Schoonjans, B. Ream, A. van Nuffelen, G. Prendergast, M. Cole, R. Bronson, D. Collen, and R.C. Mulligan. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92:2746-2755.
11. Carmeliet, P., L. Moons, V. Ploplis, E. Plow, and D. Collen. 1997. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99:200-208.
12. Lijnen, H.R., B. Van Hoef, F. Lupu, L. Moons, P. Carmeliet, and D. Collen. 1998. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler. Thromb. Vasc. Biol. 18:1035-1045.
13. Lowery, O.H., and N.J. Rosenbrough. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
14. Junqueira, L.C., G. Bignolas, and R.R. Brentani. 1979. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11:447-455.
15. Romanic, A.M., R.F. White, A.J. Arleth, E.H. Ohlstein, and F.C. Barone. 1998. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 29:1020-1030.
16. Mulligan-Kehoe, M.J., R. Wagner, C. Wieland, and R. Powell. 2001. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. J. Biol. Chem. 276:8588-8596.
17. Pinsky, D.J., H. Liao, C.A. Lawson, S.F. Yan, J. Chen, P. Carmeliet, D.J. Loskutoff, and D.M. Stern. 1998. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J. Clin. Invest. 102:919-928.
18. Stoop, A.A., F. Lupu, and H. Pannekoek. 2000. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler. Thromb. Vasc. Biol. 20:1143-1149.
19. Reidy, M.A., C. Irvin, and V. Lindner. 1996. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78:405-414.
20. Todor, D.R., I. Lewis, G. Bruno, and D. Chyatte. 1998. Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2. Stroke. 29:1580-1583.
21. Zhao, W., D.R. Spitz, L.W. Oberley, and M.E. Robbins. 2001. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res. 61:5537-5543.
22. Strandberg, L., D.A. Lawrence, L.B. Johansson, and T. Ny. 1991. The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1′ methionine. J. Biol. Chem. 266:13852-13858.
23. Lawrence, D.A., and D.J. Loskutoff. 1986. Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry. 25:6351-6355.
24. Creemers, E., J. Cleutjens, J. Smits, S. Heymans, L. Moons, D. Collen, M. Daemen, and P. Carmeliet. 2000. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am. J. Pathol. 156:1865-1873.
25. Fay, W.P., A.C. Parker, L.R. Condrey, and A.D. Shapiro. 1997. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 90:204-208.
26. Baker, M.S., S.P. Green, N. Goss, M. Katrantzis, and W.F. Doe. 1990. Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils. Biochem. Biophys. Res. Commun. 166:993-1000.
27. Kalra, D.K., X. Zhu, M.K. Ramchandani, G. Lawrie, M.J. Reardon, D. Lee-Jackson, W.L. Winters, N. Sivasubramanian, D.L. Mann, and W.A. Zoghbi. 2002. Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans. Circulation. 105:1537-1540.
28. Sivasubramanian, N., M.L. Coker, K.M. Kurrelmeyer, W.R. MacLellan, F.J. DeMayo, F.G. Spinale, and D.L. Mann. 2001. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 104:826-831.
29. Siwik, D.A., P.J. Pagano, and W.S. Colucci. 2001. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 280:C53-C60.
30. Harris, J.E., and J. Schultz. 1976. Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem. 251:1371-1374.
31. Nishimura, H., H. Tsuji, H. Masuda, K. Nakagawa, Y. Nakahara, H. Kitamura, T. Kasahara, T. Sugano, M. Yoshizumi, S. Sawada, et al. 1997. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost. 77:1189-1195.
32. Mehta, J.L., D.Y. Li, H. Yang, and M.K. Raizada. 2002. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J. Cardiovasc. Pharmacol. 39:789-794.
33. Pahor, M., L.V. Franse, S.R. Deitcher, W.C. Cushman, K.C. Johnson, R.I. Shorr, K. Kottke-Marchant, R.P. Tracy, G.W. Somes, and W.B. Applegate. 2002. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 105:457-461.
34. Raggi, P., N.R. Dickson, M. Boyne, R. Pereira, B. Cooil, N. Wattanasuwan, and D.C. Russell. 1998. Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction. Ann. Pharmacother. 32:1141-1146.
35. Lapointe, N., C. Blais, Jr., A. Adam, T. Parker, M.G. Sirois, H. Gosselin, R. Clement, and J.L. Rouleau. 2002. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J. Am. Coll. Cardiol. 39:1692-1698.
36. Gasic, S., O.F. Wagner, P. Fasching, C. Ludwig, M. Veitl, S. Kapiotis, and B. Jilma. 1999. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am. J. Hypertens. 12:217-222.
37. Nikpoor, B., G. Turecki, C. Fournier, P. Theroux, and G.A. Rouleau. 2001. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142:336-339.
38. Gardemann, A., J. Lohre, N. Katz, H. Tillmanns, F.W. Hehrlein, and W. Haberbosch. 1999. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb. Haemost. 82:1121-1126.
39. Eitzman, D.T., R.J. Westrick, Z. Xu, J. Tyson, and D. Ginsburg. 2000. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 96:4212-4215.
40. Sjoland, H., D.T. Eitzman, D. Gordon, R. Westrick, E.G. Nabel, and D. Ginsburg. 2000. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler. Thromb. Vasc. Biol. 20:846-852.
41. Zhang, R., M.L. Brennan, X. Fu, R.J. Aviles, G.L. Pearce, M.S. Penn, E.J. Topol, D.L. Sprecher, and S.L. Hazen. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2136-2142.